Compounds of the formula I ##STR00001##
in which X, Q, R.sup.1 and R.sup.2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: ##STR00001##
where R, L, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y.sup.1, Y.sup.2, Y.sup.3, and Y.sup.4 are described herein.

The present invention provides a novel indoleamine 2,3-dioxygenase inhibitor, a preparation method thereof, and a pharmaceutical composition, in which the definitions of n, Y, Z, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as stated in the specification. Also provided is a use of the aforementioned compound and pharmaceutically acceptable salts and isomers thereof in the preparation of a drug for indoleamine 2,3-dioxygenase (IDO) related disease, specifically a use in the treatment of major diseases such as cancer, Alzheimer's, depression, cataract, etc. The compound of the invention has improved activity, potential medicinal value, and wide market prospects.

The present invention provides a novel indoleamine 2,3-dioxygenase inhibitor, a preparation method thereof, and a pharmaceutical composition, in which the definitions of n, Y, Z, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as stated in the specification. Also provided is a use of the aforementioned compound and pharmaceutically acceptable salts and isomers thereof in the preparation of a drug for indoleamine 2,3-dioxygenase (IDO) related disease, specifically a use in the treatment of major diseases such as cancer, Alzheimer's, depression, cataract, etc. The compound of the invention has improved activity, potential medicinal value, and wide market prospects.

The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC.sub.50 values and permeability across the blood-brain barrier.

The present disclosure provides various compounds, compositions, and methods of BACE inhibition that interact with both BACE and APP to increase selectivity of the inhibitor. Compounds presented herein exhibit desirably low IC.sub.50 values and permeability across the blood-brain barrier.

The present invention relates to a process for the preparation of (S)-Netarsudil or its pharmaceutically acceptable salts using novel intermediates. The present invention further provides novel salts, novel intermediates and novel polymorphic forms of the (S)-Netarsudil salts and process for the preparation of the same.

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.

Disclosed herein are compounds which inhibit RIPK1, pharmaceutical compositions, and methods of treatment of RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer.